We are live on ! Find out more
RNAZ icon

TransCode Therapeutics
RNAZ

3 hedge funds and large institutions have $33.4K invested in TransCode Therapeutics in 2024 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

4.87% less ownership

Funds ownership: 4.91% → 0.04% (-4.9%)

30% less capital inflows, than outflows

Capital inflows: $124K | Capital outflows: $176K

57% less funds holding

Funds holding: 7 → 3 (-4)

80% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 5

Holders
3
Holders Change
-4
Holders Change %
-57.14%
% of All Funds
0.04%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
1
Reduced
–
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$115K
2
Tower Research Capital (TRC)
Tower Research Capital (TRC)
New York
+$9.6K

Top Sellers

Rank Fund Capital Flow
1
Geode Capital Management
Geode Capital Management
Massachusetts
-$69.5K
2
Private Capital Management (Colorado)
Private Capital Management (Colorado)
Colorado
-$46.1K
3
Sheets Smith Wealth Management
Sheets Smith Wealth Management
North Carolina
-$28.6K
4
Jane Street
Jane Street
New York
-$22.7K
5
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors
North Carolina
-$9.28K

RNAZ Hedge Fund Activity: Q4 2024 in Review

3 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in TransCode Therapeutics (RNAZ) for Q4 2024, worth a combined $33.4K — down 82% from $186K a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of RNAZ and 1 opened new positions — a net loss of 4 holders — while 0 trimmed existing stakes and 1 added.

The largest buyer was UBS Group, opening a new position worth an estimated $115K. The largest seller was Geode Capital Management, exiting entirely with an estimated $69.5K sold.

  • 3 institutional investors held TransCode Therapeutics (RNAZ) as of Q4 2024, down from 7 in Q3 2024.
  • Funds reported $33.4K of TransCode Therapeutics stock for Q4 2024, down 82% quarter-over-quarter.
  • 1 fund opened new TransCode Therapeutics positions in Q4 2024 and 5 closed out, a net change of -4 holders.
  • The largest TransCode Therapeutics buyer in Q4 2024 was UBS Group, an estimated $115K added.
  • The largest TransCode Therapeutics seller in Q4 2024 was Geode Capital Management, an estimated $69.5K sold.

Based on aggregated 13F filings for Q4 2024.